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Given the growing interest in using proton beam therapy (PBT) for hepatocellular carcinoma (HCC), it is possible that transarterial
chemoembolization (TACE) could be used for selected patients who have previously undergone PBT. However, these cases can be
technically challenging to treat and require appropriate preparation.Thus, we aimed to identify angiographic findings in this setting.
We retrospectively identified 31 patients (28 men and 3 women, mean age: 69 years, range: 43–84 years) who underwent hepatic
angiography plus TACE or transarterial infusion chemotherapy (TAI) for HCC that recurred after PBT (July 2007 to June 2018).
We discovered four angiographic findings, which we speculate were related to the previous PBT. 18 patients experienced recurrence
in the irradiated field, and 13 patients experienced recurrence outside the irradiated field. 29 patients underwent TACE and only 2
patients underwent TAI. The mean number of previous PBT treatments was 1.3 ± 0.6 (range: 1–4). The median interval from the
earliest PBT treatment to hepatic angiography was 559 days (range: 34–5,383 days), and the median interval from the latest PBT
treatment to hepatic angiography was 464 days (range: 34–5,383 days). Abnormal staining of the irradiated liver parenchyma was
observed in 22 patients, which obscured the angiographic tumor staining in 4 patients. Development of a tortuous tumor feeder
vessel was observed in 13 patients. Development of an extrahepatic collateral pathway was observed in 7 patients. Development of
an arterioportal or arteriovenous shunt was observed in 4 patients. Based on these findings, we conclude that PBT was associated
with various angiographic findings during subsequent transarterial chemotherapy for recurrent HCC, and familiarity with these
findings will be important in developing appropriate treatment plans.
1. Introduction
Hepatocellular carcinoma (HCC) is the most common pri-
mary cancer of the liver [1]. According to the NCCN
guidelines, there are numerous strategies for treating HCC,
including resection, transplantation, radiofrequency abla-
tion, transarterial chemoembolization (TACE), radiotherapy
(RT), and systemic therapy using sorafenib or lenvatinib [2].
All patients with HCC should be evaluated for potential
curative therapies, including resection and transplantation
[2]. Locoregional therapy, including ablation, TACE, and RT,
is indicated for patients who are not candidates for curative
therapy or indicated as a bridge therapy for patients who are
candidates for transplantation [2].
Recent reports have described favorable clinical outcomes
after proton beam therapy (PBT) for HCC, based on a 5-
year overall survival rate of 24–48% [3, 4] and a 5-year local
control rate of approximately 80% [3, 5]. Among the external
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beam RT modalities, PBT may be superior to X-ray therapy
based on excellent dose localization to the therapeutic target
[1]. Furthermore, given the good outcomes after PBT for
HCC, some patients may be eligible for TACE treatment of
intrahepatic HCC metastasis, while repeated PBT, TACE, or
systemic therapy may be feasible in cases of local recurrence
after PBT. Moreover, PBT is effective for patients with HCC
who also have portal vein tumor thrombus (PVTT) [6], and
the efficacy of combined therapy of TACE and RT for HCC
with PVTT has been reported [7, 8]. Therefore, given the
growing interest in using PBT for HCC, it is possible that
TACE could be used for selected patients who have previously
undergone PBT.
The purpose of our study is to evaluate the angiographic
findings from patients with HCC previously treated using
PBT. We classified abnormal PBT-related angiographic find-
ings and analyzed these factors’ frequency, onset timing, and
influence on technical difficulty.
2. Materials and Methods
This study’s retrospective protocol was approved by our
institutional review board. The requirement for informed
consent was waived.
2.1. Patient Acquisition. We identified patients who under-
went transarterial chemotherapy for HCC that recurred
after PBT between July 2007 and June 2018. 37 patients
fulfilled the inclusion criteria: (1) diagnosis of HCC was con-
firmed pathologically or clinically according to the accepted
guidelines [9], (2) PBT was performed for HCC before the
transarterial chemotherapy, and (3) TACE or transarterial
infusion chemotherapy (TAI) was performed. However, 6
patients were excluded because hepatic resection (n=3) or
radiofrequency ablation (n=3) had been performed before
the transarterial chemotherapy. Thus, the present study
included 31 patients (28 men and 3 women, mean age: 69
years, range: 43–84 years) who underwent TACE or TAI after
PBT. The patients’ records were reviewed to determine the
type of transarterial chemotherapy, the number of previous
PBT treatments, and the interval between the angiography
and the previous PBT treatment(s).
2.2. Hepatic Angiography and Transarterial Chemotherapy.
All patients routinely underwent digital subtraction angiog-
raphy of the celiac trunk and/or superior mesenteric artery,
as well as cone-beam computed tomography (CBCT) of
the proper or common hepatic artery. Angiography of an
extrahepatic artery was performed if the HCC was not
observed using hepatic arteriography or CBCT. The TACE
and TAI treatments involve a mixture of 4–10mL of iodized
oil (Lipiodol; Andre Guerbet, Aulnay-sous-Bois, France)
and the chemotherapeutic agent (cisplatin up to 50mg or
epirubicin up to 50mg and mitomycin C up to 10mg).
Gelatin sponge particles (Gelpart; Nihonkayaku, Japan) were
also used during the TACE treatment. Both procedures
were performed using 3–4-Fr shepherd hook catheters and
microcatheters with a tip diameter of 1.7–1.9 Fr.
2.3. PBT Procedure. Treatment planning for PBT was per-
formed as previously reported [3, 10]. The irradiation pro-
tocols were generally classified according to tumor location:
(1) a total dose of 77.0 GyE in 35 fractions for tumors located
<2 cm from a gastrointestinal organ, (2) a total dose of 72.6
GyE in 22 fractions for tumors located <2 cm from the
porta hepatis, or (3) a total dose of 66.0 GyE in 10 fractions
for peripheral tumors >2 cm from both the GI tract and
porta hepatis. The protocols were adjusted in some cases to
avoid excessive irradiation of the adjacent organs. All patients
received PBT on 5 days per week.
2.4. Image Analysis. We analyzed the PBT-related angio-
graphic findings in each case (based on their relationship
to the PBT irradiation field) and categorized them into
four types: (1) abnormal staining of the irradiated liver
parenchyma, (2) development of tortuous tumor feeder
vessels, (3) development of an extrahepatic collateral pathway
to the liver, and (4) development of arterioportal (AP) or
arteriovenous (AV) shunts. Intrahepatic and extrahepatic
shunts observed in the PBT irradiation field were both
included in the study. The four PBT-related angiographic
findings were counted for each case, although findings that
were not clearly related to the PBT irradiation field were not
considered. The HCCs targeted during TACE or TAI were
classified according to whether they were in or outside the
previous PBT irradiation field. All characteristics were judged
based on mutual agreement between two radiologists (HT: 8
years of experience, KM: 25 years of experience).
2.5. Statistical Analysis. Differences in the distributions of the
angiographic findings were evaluated using the chi-squared
test. All data were analyzed using R software (version 3.3.2).
Differences were considered statistically significant at P-
values of <0.05.
3. Results
Table 1 shows the 31 patients’ characteristics. 18 patients
experienced recurrence in the irradiated field and 13 patients
experienced recurrence outside the irradiated field. Most
patients underwent TACE (29 patients) and only 2 patients
underwent TAI. The average age was 68.5 ± 9.8 years (range:
43–84 years). The mean number of previous PBT treatments
was 1.3 ± 0.6 (range: 1–4). The median interval from the
earliest PBT treatment to the angiography was 559 days
(range: 34–5,383 days), and the median interval from the
latest PBT treatment was 464 days (range: 34–5,383 days).
The relationships between the PBT-related angiographic
findings and the HCC characteristics are summarized in
Table 2. In the PBT irradiation fields, we identified four
angiographic findings: (1) abnormal staining of the irradiated
liver parenchyma, (2) development of a tortuous tumor
feeder vessel, (3) development of an extrahepatic collateral
pathway, and (4) development of AP or AV shunts. Abnormal
staining of the irradiated liver parenchyma was observed
in 22 patients, and the angiographic tumor staining was
obscured by the abnormal parenchymal staining in 4 patients
(Figure 1). In all 4 patients, the CBCT could identify the
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Table 1: Patient characteristics.
Total patients 31
Procedure
TACE 29 (93.5)
TAI 2 (6.5)
Male sex 28 (90.3)
Age at TACE or TAI, years 68.5 ± 9.8 (43–84)
Child-Pugh
A 28 (90.3)
B 3 (9.7)
C 0 (0)
Previous PBT treatments
1 25 (80.6)
2 5 (16.1)
3 0 (0)
4 1 (3.2)
Diameter of HCC treated using PBT, mm 37.5 ± 26.6 (8-122)
Median follow-up time aer earliest PBT, days 559 (34–5,383)
Median follow-up time aer latest PBT, days 464 (34–5,383)
Targeted HCCs in TACE or TAI
Irradiated HCCs targeted 18
Irradiated HCCs not targeted 13
PBT-related ﬁndings
Abnormal staining of irradiated liver parenchyma 22 (71.0)
Development of tortuous tumor feeder 13 (41.9)
Development of extrahepatic collateral pathway 7 (22.6)
Development of AP/AV shunt 4 (12.9)
Data are reported as number (percentage), median (range) or mean ± standard deviation.
TACE: transarterial chemoembolization, TAI: transcatheter arterial infusion, PBT: proton beam therapy, HCC: hepatocellular carcinoma, AP/AV: arterio-
portal or arteriovenous.
Table 2: The prevalence of PBT-related angiographic findings at the initial hepatic angiography according to HCC targeting.
Angiographic findings Total(n=31)
Irradiated HCCs targeted
during TACE or TAI
(n=18)
Irradiated HCCs
NOT targeted during
TACE or TAI (n=13)
𝑃
Abnormal staining of irradiated
liver parenchyma 22 (71%) 14 (78%) 8 (62%) 0.326
Development of tortuous tumor
feeder 13 (42%) 13 (72%) 0 (0%) <0.001
Development of extrahepatic
collateral pathway 7 (23%) 5 (28%) 2 (15%) 0.415
Development of AP/AV shunt 4 (13%) 4 (22%) 0 (0%) 0.069
The chi-squared test was used to calculate p-values. Irradiated HCCs refer to the TACE/TAI-targeted tumors being within the PBT irradiation field.
TACE: transarterial chemoembolization, TAI: transcatheter arterial infusion, PBT: proton beam therapy, HCC: hepatocellular carcinoma, AP/AV: arterio-
portal or arteriovenous.
tumors and their feeding arteries. Among the 22 patients
with abnormal parenchymal staining, the median interval
from the earliest PBT treatment to the angiography was
629 days (range: 109–3,163 days) and the median time from
the latest PBT treatment was 466.5 days (range: 109–3,163
days) (Table 3). Development of a tortuous tumor feeder
vessel was observed in 13 patients, and in all cases the HCCs
had recurred in the PBT irradiation field (Figures 1 and
2, Table 2). Among these 13 patients, the median interval
from the earliest PBT treatment to the angiography was 911
days (range: 381–2,938 days), and the median interval from
the latest PBT treatment was 559 days (range: 381–2,938
days) (Table 3). Development of an extrahepatic collateral
pathway was observed in 7 patients, which involved the
right inferior phrenic artery (6 patients) (Figure 3) or the
omental artery (1 patient), and all collateral pathways fed
the irradiated HCC or/and irradiated liver parenchyma.
All the 7 patients only underwent a single PBT treatment,
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Table 3: Relationship between PBT-related angiographic findings and the elapsed time after PBT treatment.
All patients Single PBT treatment(n=25)
Multiple PBT treatments
(n=6)
Follow-up
after first
PBT, days
Follow-up
after last PBT,
days
N
Follow-up
after PBT,
days
N
Follow-up
after first
PBT, days
Follow-up
after last PBT,
days
Abnormal staining of
irradiated liver
parenchyma (n=22)
629
(109–3,163)
466.5
(109–3,163) 17
477
(109–3,163) 5
225
(464–720)
877
(1,274–1,950)
Development of tortuous
tumor feeder (n=13)
911
(381–2,938)
559
(381–2,938) 9
699
(381–2,938) 4
466.5
(441–720)
1,284.5
(911–1,950)
Development of
extrahepatic collateral
pathway (n=7)
917
(418–31,63)
917
(418–3,163) 7
917
(418–3,163) 0 N/A N/A
Development of AP/AV
shunt (n=4)
588
(397–1,443)
588
(397–1,443) 4
588
(397–1,443) 0 N/A N/A
Data are reported as median (range).
TACE: transarterial chemoembolization, TAI: transcatheter arterial infusion, PBT: proton beam therapy, HCC: hepatocellular carcinoma, AP/AV: arterio-
portal or arteriovenous.
Figure 1: A 70-year-old woman underwent her first and second proton beam therapy (PBT) treatment for hepatocellular carcinoma (HCC)
in S7 43 months (1) and 16 months (not shown) before the angiography, respectively. Dynamic computed tomography before the transarterial
chemoembolization revealed local recurrence of the PBT-treated HCC, with early enhancement at the hepatic arterial phase and washout
at the equilibrium phase (arrow). The surrounding irradiated parenchyma exhibited delayed enhancement (arrowhead) (2,3). A tortuous
tumor feeder was noted during the procedure (4), although enhancement of the recurrent HCCwas obscured by the abnormal staining of the
irradiated liver parenchyma (5). Cone-beam computed tomography clearly showed that the selected artery fed the recurrent tumor (white
arrow) (6).
and the median intervals from the PBT treatments to the
angiography were both 917 days (range: 418–3,163 days)
(Table 3). Development of AP or AV shunts was observed
in 4 patients, which involved an AP shunt (2 patients), an
AV shunt to the hepatic vein (1 patient), and an AV shunt to
the pulmonary vein (1 patient) (Figure 3). All the 4 patients
only underwent a single PBT treatment, and the median
intervals from the earliest and latest PBT treatments to the
angiography were both 588 days (range: 397–1,443 days)
(Table 3).
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Figure 2: A 55-year-old man underwent proton beam therapy (PBT) for hepatocellular carcinoma (HCC) in S5 29 months before the
angiography procedure (1). Dynamic computed tomography revealed local recurrence of the PBT-treated HCC (arrow) at the hepatic
arterial phase (2). The recurrent HCC exhibited clear tumor staining during the procedure, with several tortuous vessels feeding the lesion
(arrowhead), which made it technically difficult to perform selective catheterization (3).
Figure 3: A 66-year-old man underwent his first proton beam therapy (PBT) treatment for hepatocellular carcinoma (HCC) in S8/1 48
months before the angiography procedure (1). Computed tomography revealed radiation-induced pneumonitis in the medial side of the right
lower lung (2). An extrahepatic collateral pathway (via right inferior phrenic artery, RIPA) and an arteriovenous shunt for the pulmonary vein
were noted during the procedure (3).The location of the arteriovenous shunt corresponded to the site of the radiation-induced pneumonitis.
6 Journal of Oncology
4. Discussion
The present study identified four angiographic findings that
were observed during transarterial chemotherapy, which was
performed for HCCs that recurred after PBT. Interestingly,
these four findings seem to appear at different intervals
after the PBT. Among patients who underwent a single
PBT treatment, the earliest finding was abnormal staining
of the liver parenchyma (median interval: 477 days), the
development of AV or AP shunts occurred later (median
interval: 588 days), the development of tortuous feeder vessels
occurred even later (median interval: 699 days), and the
development of extrahepatic collateral pathways was the
latest finding (median interval: 917 days).
Abnormal staining of irradiated liver parenchymawas the
most common PBT-related angiographic finding in our study
(22 out of 31 cases, 71%), which appeared as an areawith dense
and prolonged staining. Irradiated hepatic parenchyma after
PBT can be observed as low-attenuation areas on noncontrast
CT or areas with early and prolonged enhancement on
dynamic CT [11]. During angiography-assisted CT, irradiated
parenchyma exhibits decreased attenuation on CT arterial
portography and increased attenuation on CT arteriogra-
phy, which is the result of an arterial-predominant blood
supply to the irradiated parenchyma (caused by radiation-
induced venoocclusive disease) [11–13]. Prolonged enhance-
ment of the irradiated parenchyma is related to contrast
agent retention in the fibrous tissue [14]. Furthermore, a
previous study demonstrated that the earliest disappearance
of radiation-induced hepatic injury on imaging was observed
42 months after the PBT [11–13], which suggests that the
irradiated parenchymamight have diminished arterial supply
that persists long after the PBT treatment. These previously
reported results agreewith our findings, aswe found early and
prolonged abnormal staining of the irradiated parenchyma
during angiography, which occurred at a relatively short
interval after PBT. Moreover, we found that the irradiated
liver parenchyma appeared as a pseudo-lesion in some cases
and obscured the tumor staining in other cases. When the
abnormal parenchymal staining obscured the tumor staining,
CBCT was useful for detecting the tumor and its feeder
vessels [15, 16].
Development of tortuous tumor feeder vessels was
another PBT-related angiographic finding in the present
study, and this characteristic was exclusively observed when
the TACE or TAI targeted HCCs in the PBT irradiated field.
Therefore, development of tortuous tumor feeder is likely to
be associated with PBT-treated HCCs local recurrence. In
addition, a previous report has described the local control
rates of PBT-treated HCC (1-year: 98%, 3-year: 87%, 5-year:
81%) [3], which seems to be aligned with the mid-to-late
development of tortuous tumor feeder vessels. According to
our clinical experience, we speculate that selective catheter-
ization becomes technically difficult when these vessels are
present. Therefore, careful planning and attention are neces-
sary when treating HCCs in the PBT irradiated field.
The present study revealed that extrahepatic collateral
development could occur after PBT. In this context, pre-
vious reports have indicated that repeated transcatheter
intervention could cause hepatic artery occlusion and the
development of extrahepatic collaterals [17–19]. In our study,
the right inferior phrenic artery or omental artery was
developed to supply the irradiated liver parenchyma, without
obstruction of any hepatic arteries. Thus, it is possible that
extrahepatic collateral development after PBT might be the
result of diaphragm or omentum irradiation. Furthermore,
embolization of the adjacent organs should be avoided for
patients who require embolization through an extrahepatic
collateral feeder vessel [17].Therefore, it is important to iden-
tify any extrahepatic collateral arteries using the pretreatment
CT when planning TACE or TAI for patients with HCC that
were previously treated using PBT.
Attention should also be paid to the development of AP
and AV shunts, although it was less frequent than the other
findings in patients with PBT-treated HCC. Nevertheless,
TACE for HCC with AP or AV shunts can increase the
risk of life-threatening complications, such as lung damage
and pulmonary embolism [18, 20]. Lipiodol-related cerebral
embolism is also known to occur in cases with artery-
pulmonary vein shunts [21].Thus, efflux of the embolic agent
into the shunts should be avoided [20, 22], which might
be achieved via prophylactic embolization of the AP shunt
before TACE [22, 23]. Balloon-assisted TACE might also be
useful when treating cases with AP shunts [22, 24].
The present study has several limitations. First, we did
not evaluate angiographic findings before PBT, which raises
the possibility that some of the angiographic findings were
present before PBT (especially extrahepatic collateral path-
ways or AP and AV shunts). Second, the intervals between
PBT and transarterial chemotherapy varied in each case.
Thus, in order to accurately assess the onset period for each
finding, it would be preferable to perform angiography at
defined intervals after PBT. Third, the relationship between
the radiation dose and angiographic findings could not be
analyzed, as some of patients underwent multiple PBT treat-
ments. Thus, well-designed prospective studies are needed to
address these limitations and validate our findings.
5. Conclusions
In conclusion, PBT was associated with various angiographic
findings that were observed during transarterial chemother-
apy for HCC recurrence. Irradiated liver parenchyma
appeared as a pseudo-lesion during angiography or obscured
the tumor staining in some cases. In addition, tortuous
tumor feeder vessels, extrahepatic collateral pathways, and
AV and AP shunts were also observed. Familiarity with
these angiographic findings may help radiologists develop
appropriate treatment plans for patients with PBT-treated
HCC recurrence.
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